Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: A meta-analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 10, 2008, Pages 2773-2781

  Pabalan, Noel ^b   Bapat, Bharati ^a   Sung, Lillian ^d   Jarjanazi, Hamdi ^a,b,c   Francisco Pabalan, Ofelia ^e   Ozcelik, Hilmi ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1;

AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; ETHNIC DIFFERENCE; GENE DOSAGE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE ENVIRONMENT INTERACTION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HOMOZYGOSITY; HUMAN; NEOPLASM; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; UROGENITAL TRACT CANCER; ALLELE; CHI SQUARE DISTRIBUTION; ETHNOLOGY; GENETICS; GENOTYPE; META ANALYSIS; RISK FACTOR; STATISTICS;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; CYCLIN D1; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HUMANS; NEOPLASMS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 54249107683     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0169     Document Type: Article

References (80)

1. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108.
2. Burd CJ, Petre CE, Morey LM, et al. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci U S A 2006;103:2190-5.
3. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 2003;63:7056-61.
4. Zukerberg LR, Yang WI, Gadd M, et al. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol 1995;8:560-7.
5. Salesiotis AN, Cullen KJ. Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging. Curr Opin Oncol 2000;12:229-39.
6. Solomon DA, Wang Y, Fox SR, et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 2003;278:30339-47.
7. Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med 2005;24:1291-306.
8. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
10. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Int Med 1997;127:820-6.
11. Berman NG, Parker RA. Meta-analysis: neither quick nor easy. BMC Med Res Method 2002;2:10.
12. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988;7:889-94.
13. Ceschi M, Sun CL, Van Den Berg D, Koh WP, Yu MC, Probst-Hensch N. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis 2005;26:1457-64.
14. Forsti A, Angelini S, Festa F, et al. Single nucleotide polymorphisms in breast cancer. Oncol Rep 2004;11:917-22.
15. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-4.
16. Krippl P, Langsenlehner U, Renner W, et al. The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat 2003;82:165-8.
17. Onay VU, Briollais L, Knight JA, et al. SNP-SNP interactions in breast cancer susceptibility. BMC Cancer 2006;6:114.
18. Shu XO, Moore DB, Cai Q, et al. Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev 2005;14:91-7.
19. Yu CP, Yu JC, Sun CA, Tzao C, Ho JY, Yen AM. Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat 2008;107:95-102.
20. Bala S, Peltomaki P. CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res 2001;61:6042-5.
21. Grieu F, Malaney S, Ward R, Joseph D, Iacopetta B. Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res 2003;23:4257-9.
22. Grunhage F, Jungck M, Lamberti C, et al. Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. Int J Colorectal Dis 2008;23:147-54.
23. Hong Y, Eu KW, Seow-Choen F, Fook-Chong S, Cheah PY. GG genotype of cyclin D1 G870A polymorphism is associated with increased risk and advanced colorectal cancer in patients in Singapore. Eur J Cancer 2005;41:1037-44.
24. Huang WS, Tang R, Lin PY, et al. Impact of the cyclin D1 A870G polymorphism on susceptibility to sporadic colorectal cancer in Taiwan. Dis Colon Rectum 2006;49:602-8.
25. Jiang J, Wang J, Suzuki S, et al. Elevated risk of colorectal cancer associated with the AA genotype of the cyclin D1 A870G polymorphism in an Indian population. J Cancer Res Clin Oncol 2006;132:193-9.
26. Kong S, Wei Q, Amos CI, et al. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst 2001;93:1106-8.
27. Kruger S, Engel C, Bier A, et al. Absence of association between cyclin D1 (CCND1) G870A polymorphism and age of onset in hereditary nonpolyposis colorectal cancer. Cancer Lett 2006;236:191-7.
28. Le Marchand L, Seifried A, Lum-Jones A, Donlon T, Wilkens LR. Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. JAMA 2003;290:2843-8.
29. Lewis RC, Bostick RM, Xie D, et al. Polymorphism of the cyclin D1 gene, CCND1, and risk for incident sporadic colorectal adenomas. Cancer Res 2003;63:8549-53.
30. McKay JA, Douglas JJ, Ross VG, et al. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer 2000;88:77-81.
31. Porter TR, Richards FM, Houlston RS, et al. Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. Oncogene 2002;21:1928-33.
32. Probst-Hensch NM, Sun CL, Van Den BergD, Ceschi M, Koh WP, Yu MC. The effect of the cyclin D1 (CCND1) A870G polymorphism on colorectal cancer risk is modified by glutathione-S-transferase polymorphisms and isothiocyanate intake in the Singapore Chinese Health Study. Carcinogenesis 2006;27:2475-82.
33. Schernhammer ES, Tranah GJ, Giovannucci E, et al. Cyclin D1 A870G polymorphism and the risk of colorectal cancer and adenoma. Br J Cancer 2006;94:928-34.
34. Talseth BA, Ashton KA, Meldrum C, et al. Aurora-A and Cyclin D1 polymorphisms and the age of onset of colorectal cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 2008;122:1273-7.
35. Dhar KK, Branigan K, Howells RE, et al. Prognostic significance of cyclin D1 gene (CCND1) polymorphism in epithelial ovarian cancer. Int J Gynecol Cancer 1999;9:342-7.
36. Jeon YT, Kim JW, Song JH, et al. Cyclin D1 G870A polymorphism and squamous cell carcinoma of the uterine cervix in Korean women. Cancer Lett 2005;223:259-63.
37. Kang S, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Cyclin D1 polymorphism and the risk of endometrial cancer. Gynecol Oncol 2005;97:431-5.
38. Holley SL, Matthias C, Jahnke V, Fryer AA, Strange RC, Hoban PR. Association of cyclin D1 polymorphism with increased susceptibility to oral squamous cell carcinoma. Oral Oncol 2005;41:156-60.
39. Sathyan KM, Nalinakumari KR, Abraham T, Kannan S. Influence of single nucleotide polymorphisms in H-Ras and cyclin D1 genes on oral cancer susceptibility. Oral Oncol 2006;42:607-13.
40. Wong YK, Lin SC, Chang CS, et al. Cyclin D1 genotype in areca-associated oral squamous cell carcinoma. J Oral Pathol Med 2003;32:265-70.
41. Casson AG, Zheng Z, Evans SC, et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer 2005;104:730-9.
42. Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, Mittal B. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect Prev 2007;31:225-32.
43. Yu C, Lu W, Tan W, et al. Lack of association between CCND1 G870A polymorphism and risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2003;12:176.
44. Zhang J, Li Y, Wang R, et al. Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int J Cancer 2003;105:281-4.
45. Geddert H, Kiel S, Zotz RB, et al. Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol 2005;131:803-8.
46. Song JH, Kim CJ, Cho YG, et al. Association of cyclin D1 G870A polymorphism with susceptibility to gastric cancers in Korean male patients. Neoplasma 2007;54:235-9.
47. Hou X, Wang S, Zhou Y, et al. Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Int J Hematol 2005;82:206-9.
48. Howe D, Lynas C. The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica 2001;86:563-9.
49. Wang SS, Cozen W, Severson RK, et al. Cyclin D1 splice variant and risk for non-Hodgkin lymphoma. Hum Genet 2006;120:297-300.
50. Ito M, Habuchi T, Watanabe J, et al. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. Urology 2004;64:74-8.
51. Ryk C, Kumar R, Sanyal S, et al. Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett 2006;241:142-9.
52. Sanyal S, Festa F, Sakano S, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 2004;25:729-34.
53. Wang L, Habuchi T, Takahashi T, et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 2002;23:257-64.
54. Koike H, Suzuki K, Satoh T, et al. Cyclin D1 gene polymorphism and familial prostate cancer: the AA genotype of A870G polymorphism is associated with prostate cancer risk in men aged 70 years or older and metastatic stage. Anticancer Res 2003;23:4947-51.
55. Wang L, Habuchi T, Mitsumori K, et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 2003;103:116-20.
56. Yu J, Habuchi T, Tsuchiya N, et al. Association of the cyclin D1 gene G870A polymorphism with susceptibility to sporadic renal cell carcinoma. J Urol 2004;172:2410-3.
57. Buch S, Zhu B, Davis AG, et al. Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract. Mol Carcinog 2005;42:222-8.
58. Gautschi O, Hugli B, Ziegler A, et al. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2006;51:303-11.
59. Hung RJ, Boffetta P, Canzian F, et al. Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case-control study in central Europe. Cancer Res 2006;66:8280-6.
60. Qiuling S, Yuxin Z, Suhua Z, Cheng X, Shuguang L, Fengsheng H. Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis 2003;24:1499-503.
61. Sobti RC, Kaur P, Kaur S, et al. Effects of cyclin D1 (CCND1) polymorphism on susceptibility to lung cancer in a North Indian population. Cancer Genet Cytogenet 2006;170:108-14.
62. Deng L, Zhao XR, Pan KF, et al. Cyclin D1 polymorphism and the susceptibility to NPC using DHPLC. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2002;34:16-20.
63. Matthias C, Branigan K, Jahnke V, et al. Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 1998;4:2411-8.
64. Rydzanicz M, Golusinski P, Mielcarek-Kuchta D, Golusinski W, Szyfter K. Cyclin D1 gene (CCND1) polymorphism and the risk of squamous cell carcinoma of the larynx. Eur Arch Otorhinolaryngol 2006;263:43-8.
65. Zheng Y, Shen H, Sturgis EM, et al. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis 2001;22:1195-9.
66. Correa P, Lundgren E, Rastad J, Akerstrom G, Westin G, Carling T. The NeiI polymorphism in the cyclin D1 gene and sporadic primary hyperparathyroidism. J Intern Med 2001;250:516-20.
67. Gazioglu NM, Erensoy N, Kadioglu P, et al. Altered cyclin D1 genotype distribution in human sporadic pituitary adenomas. Med Sci Monit 2007;13:CR457-63.
68. Festa F, Kumar R, Sanyal S, et al. Basal cell carcinoma and variants in genes coding for immune response, DNA repair, folate and iron metabolism. Mutat Res 2005;574:105-11.
69. Han J, Colditz GA, Hunter DJ. Lack of associations of selected variants in genes involved in cell cycle and apoptosis with skin cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:592-3.
70. Pakakasama S, Chen TT, Frawley W, et al. CCND1 polymorphism and age of onset of hepatoblastoma. Oncogene 2004;23:4789-92.
71. Zhang YJ, Chen SY, Chen CJ, Santella RM. Polymorphisms in cyclin D1 gene and hepatocellular carcinoma. Mol Carcinog 2002;33:125-9.
72. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ Clin Res Ed 2000;320:1574-7.
73. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
74. Gijtenbeek JM, Boots-Sprenger SH, Franke B, Wesseling P, Jeuken JW. Cyclin D1 genotype and expression in sporadic hemangioblastomas. J Neurooncol 2005;74:261-6.
75. Simpson DJ, Fryer AA, Grossman AB, et al. Cyclin D1 (CCND1) genotype is associated with tumour grade in sporadic pituitary adenomas. Carcinogenesis 2001;22:1801-7.
76. Wang R, Zhang JH, Li Y, Wen DG, He M, Wei LZ. The association of cyclin D1 (A870G) polymorphism with susceptibility to esophageal and cardiac cancer in north Chinese population. Zhonghua Yi Xue Za Zhi 2003;83:1089-92.
77. Azzam A, Mathews CA. Meta-analysis of the association between the catecholamine-O-methyl-transferase gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 2003;123B:64-9.
78. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995;11:1005-11.
79. Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000;60:249-52.
80. Onay UV, Aaltonen K, Briollais L, et al. Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer 2008;8:6.